|Table of Contents|

Corralation between metabolic symdrome and the occurrence and severity of differentiated thyroid carcinoma

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2023 13
Page:
2443-2447
Research Field:
Publishing date:

Info

Title:
Corralation between metabolic symdrome and the occurrence and severity of differentiated thyroid carcinoma
Author(s):
HE Qingyuan1; YAN Huiming2
1.The Second Clinical Medicial School,Shanxi Medicial University,Shanxi Taiyuan 030000,China;2.Department of General Surgery,the School Hospital of Shanxi Medicial University,Shanxi Taiyuan 030000,China.
Keywords:
metabolic syndrome; differentiated thyroid carcinoma; clinicopathological characteristics
PACS:
R736.1
DOI:
10.3969/j.issn.1672-4992.2023.13.013
Abstract:
Objective:To investigate the correlation between metabolic syndrome and its components and the occurrence and severity of differentiated thyroid carcinoma.Methods:The clinical data of 423 patients underwent surgical treatment for thyroid nodules during June 2020 and June 2022 were retrospectively collected.According to the pathological results,they were divided into 138 cases of benign nodule and 285 cases of malignant nodule.According to whether they had metabolic syndrome,285 cases of malignant nodule were divided into 156 cases of differentiated thyroid carcinoma and 129 cases of differentiated thyroid carcinoma combined with metabolic syndrome.Results:The mean BMI and the proportion of metabolic syndrome in the malignant group were significantly higher than those in the benign group,and the mean age in the malignant group was lower than that in the benign group(P＜0.05).The mean of body mass index,blood pressure,fasting blood glucose,triglyceride,and number of tumor size≥1,tumor in bilateral thyroid,multifocal tumor in patients with differentiated thyroid cancer combined with metabolic syndrome were higher than those in patients without metabolic syndrome(P＜0.05),and the level of high-density lipoprotein cholesterol was lower(P＜0.05).Conclusion:The thyroid nodules patients with metabolic syndrome were more likely to be malignant than those without metabolic syndrome,and showed more serious tendency in tumor size,tumor location,and number of cancer foci,suggesting that metabolic syndrome may be a risk factor affecting the severity of thyroid malignant tumors.

References:

[1]LIM H,DEVESA SS,SOSA JA,et al.Trends in thyroid cancer incidence and mortality in the United States,1974-2013［J］.JAMA,2017,317(13):1338-1348.
[2]CHEN W,ZHENG R,ZHANG S,et al.Cancer incidence and mortality in China in 2013:an analysis based on urbanization level［J］.Chin J Cancer Res,2017,29(1):1-10.
[3] SEIB CD,SOSA JA.Evolving understanding of the epidemiology of thyroid cancer［J］.Endocrinol Metab Clin North Am,2019,48(1):23-35.
[4]HIRODE G,WONG RJ.Trends in the prevalence of metabolic syndrome in the United States,2011-2016［J］.JAMA,2020,323(24):2526-2528.
[5] SAEEDI P,PETERSOHN I,SALPEA P,et al.IDF diabetes atlas committee.Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045:Results from the International Diabetes Federation Diabetes Atlas,9th edition［J］.Diabetes Res Clin Pract,2019,157:107843.
[6] POTHIWALA P,JAIN SK,YATURU S.Metabolic syndrome and cancer［J］.Metab Syndr Relat Dis,2009,7(4):279-288.
[7] ESPOSITO K,CHIODINI P,CAPUANO A,et al.Metabolic syndrome and postmenopausal breast cancer:systematic review and meta-analysis［J］.Menopause,2013,20(12):1301-1309.
[8] RUSSO A,AUTELITANO M,BISANTI L.Metabolic syndrome and cancer risk［J］.Eur J Cancer,2008,44(2):293-297.
[9]LUND HAHEIM L,WISLOFF TF,HOLME L,et al.Metabolic syndrome predicts prostate cancer in a cohort of middle-aged Norwegian men followed for 27 years［J］.Am J Epidemiol,2006,164(8):769-774.
[10] AYTURK S,GURSOY A,KUT A,et al.Metabolic syndrome and its components are associated with increased thyroid volume and nodule prevalence in a mild-to-moderate iodine-deficient area［J］.Eur J Endocri-nol,2009,161(4):599-605.
[11]ALBERTI KG,ECKEL RH,GRUNDY SM,et al.Harmonizing the metabolic syndrome:a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention,National Heart,Lung,and Blood Institute,American Heart Association,World Heart Federation,International Atherosclerosis Society,and International Association for the Study of Obesity［J］.Circulation,2009,120(16):1640-1645.
[12]KITAHARA CM,PLATZ EA,FREEMAN LE,et al.Obesity and thyroid cancer risk among U.S.men and women:a pooled analysis of five prospective studies［J］.Cancer Epidemiol Biomarkers Prev,2011,20(3):464-472.
[13]ZHAO S,JIA X,FAN X,et al.Association of obesity with the clinicopathological features of thyroid cancer in a large,operative population:a retrospective case-control study［J］.Medicine,2019,98(50):e18213.
[14]P RANASINGHE,Y MATHANGASINGHE,R JAYAWARDENA,et al.Prevalence and trends of metabolic syndrome among adults in the Asia-pacific region:a systematic review［J］.BMC Public Health,2017,17(1):101.
[15]SEQUI-DOMINGUEZ I,ALVAREZ-BUENO C,MARTINEZ-VIZCAINO V,et al.Effectiveness of mobile health interventions promoting physical activity and lifestyle interventions to reduce cardiovascular risk among individuals with metabolic syndrome:Systematic review and Meta-analysis［J］.J Med Internet Res,2020,22(8):e17790.
[16]FM MENDONCA,FR DE SOUSA,AL BARBOSA,et al.Metabolic syndrome and risk of cancer:which link［J］.Metabolism,2015,64(2),182-189.
[17]K ESPOSITO,P CHIODINI,A COLAO,et al.Metabolic syndrome and risk of cancer:a systematic review and meta-analysis［J］.Diabetes Care,2012,35(11):2402-2411.
[18]LEE JS,CHO SI,PARK HS.Metabolic syndrome and cancer-related mortality among Korean men and women［J］.Ann Oncol,2010,21(3):640-645.
[19]CHEN DZ,JI FY,XU QM,et al.Interaction of smoking and metabolic syndrome in increasing the recurrence risk of colorectal cancer in a Chinese male cohort:a retrospective study ［J］.Scientific Reports,2018,8(1):972.
[20] 霍瑞雪,崔宇,吴晓静,等.炎症介质及炎症细胞因子在结直肠癌发生发展中作用的研究进展 ［J］.山东医药,2020,60(3):110-113. HUO RX,CUI Y,WU XJ,et al.Research progress in the role of inflammatory mediators and inflammatory cytokines in the occurrence and development of colorectal cancer ［J］.Shandong Medical Journal，2020,60(3):110-113.
[21] 高鹰,孙绍梅,魏玮,等.肿瘤患者肥胖状态下代谢综合征及其组分聚集风险分析［J］.现代肿瘤医学，2021,29(18):1374-1377. GAO Y,SUN SM,WEI W,et al.Association of metabolic syndrome and its components clustered risk in tumor patients with obesity status［J］.Modern Oncology,2021,29(18):1374-1377.
[22] PARK JH,CHO HS,YOON JH.Thyroid cancer in patients with metabolic syndrome or its components:A nationwide population-based cohort study［J］.Cancers(Basel),2022,14(17):4106.
[23]SONG JL,LI LR,YU XZ,et al.Association between metabolic syndrome and clinicopathological features of papillary thyroid cancer［J］.Endocrine,2022,75(3),865-871.
[24]C MIELE,JJ ROCHFORD,N FILIPPA,et al.Insulin and insulin-like growth factor-I induce vascular endothelial growth factor mRNA expression via different signaling pathways［J］.J Biol Chem,2000,275(28):21695-21702.
[25]L MANZELLA,M MASSIMINO,S STELLA,et al.Activation of the IGF axis in thyroid cancer:implications for tumorigenesis and treatment［J］.Int J Mol Sci,2019,20(13):3258.
[26] G REVILLA,L CEDO,M TONDO,et al.LDL,HDL and endocrine-related cancer:From pathogenic mechanisms to therapies［J］.Semin Cancer Biol,2021,73:134-157.
[27]SAHA A,AHN S,BLANDO J,et al.Proinflammatory CXCL12-CXCR4/CXCR7 signaling axis drives Myc-induced prostate cancer in obese mice［J］.Cancer Res,2017,77(18):5158-5168.
[28]GALVAN GC,JOHNSON CB,PRICE RS,et al.Effects of obesity on the regulation of macrophage population in the prostate tumor microenvironment［J］.Nutr Cancer,2017,69(7):996-1002.
[29]AR SALTIEL,JM OLEFSKY.Inflammatory mechanisms linkingobesity and metabolic disease［J］.J Clin Invest,2017,127(1):1-4.
[30]M TAFANI,E DE SANTIS,L COPPOLA,et al.Bridging hypoxia,inflammation and estrogen receptors in thyroid cancer progression［J］.Biomed Pharmacother,2014,68(1):1-5.

Memo

Memo:
-
Last Update: 2023-05-31